Contraindications of Megestrol Acetate in Cancer Patients
The only absolute contraindication to megestrol acetate in cancer patients is a history of hypersensitivity to megestrol acetate or any component of the formulation 1.
Key Clinical Context
While there is only one formal contraindication, megestrol acetate carries significant risks that warrant careful consideration before prescribing:
Major Risks to Consider
Thromboembolic Events:
- Megestrol acetate is associated with increased risk of thromboembolic events (RR 1.84; 95% CI 1.07-3.18) 2
- Deep vein thrombosis occurred in 11.3% of cancer patients receiving MA with chemotherapy 3
- A cluster study showed 32% of nursing home residents on MA developed proximal deep vein thrombosis, with most cases occurring after 50 days of treatment 4
- Recent data from Korean patients with biliary-pancreatic cancer showed rising thrombosis rates correlating with increased MA prescriptions 5
Adrenal Insufficiency:
- MA has glucocorticoid-like effects causing substantial suppression of the hypothalamic-pituitary-adrenal axis 6, 7
- This can be symptomatic and potentially life-threatening 6
- In male patients, MA also suppresses the gonadal axis, causing symptomatic androgen deficiency 6
- Adrenal insufficiency can occur during therapy or after abrupt withdrawal; MA should be tapered upon discontinuation 8
- Patients may require stress-dose corticosteroids during surgery, procedures, or acute illness 8
Other Significant Risks:
- Edema (RR 1.36; 95% CI 1.07-1.72) 2
- Increased risk of death in meta-analysis (RR 1.42; 95% CI 1.04-1.94) 2
- Severe osteoporosis with vertebral fractures reported in patients on high-dose therapy 7
Clinical Decision Algorithm
When NOT to prescribe megestrol acetate:
- Known hypersensitivity (absolute contraindication)
- Active thromboembolic disease or high thrombotic risk
- Patients with short life expectancy where corticosteroids may be more appropriate 2
- When progestin IUD is an option for fertility-sparing endometrial cancer treatment (preferred to avoid systemic effects) 8
When to consider prescribing (with caution):
- Advanced cancer with anorexia/cachexia after failure of dietary management 9
- Dose: 160-480 mg/day (160 mg appears optimal; no benefit above 480 mg) 9
- Duration: Short-term trial recommended given toxicity profile 2
- Monitor closely for thrombosis, especially after 50 days of treatment 4
- Consider prophylactic anticoagulation in high-risk patients
- Taper when discontinuing to prevent adrenal crisis 8
Important caveat: The 2020 ASCO guidelines note that evidence remains insufficient to strongly endorse any pharmacologic agent for cancer cachexia, and clinicians may choose not to offer medications at all 2. There are currently no FDA-approved medications specifically for cancer cachexia 2. The weight gain from MA is primarily adipose tissue rather than skeletal muscle 2.